Clinical Trials Logo

FGFR3 Gene Mutation clinical trials

View clinical trials related to FGFR3 Gene Mutation.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05052372 Terminated - Bladder Cancer Clinical Trials

Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

Start date: November 21, 2021
Phase:
Study type: Observational

Bladder cancers are associated with genetic mutations that are present in the patient's bladder or urothelium, the lining of the lower urinary tract. Fibroblast growth factor (FGFR) alterations are present in approximately one in five patients with recurrent and refractory bladder cancer. This study will collect biomarker data from subjects receiving erdafitinib to further investigate the relationship between treatment with erdafitinib and clinical response, progression, and/or genetic alterations.

NCT ID: NCT02706691 Terminated - Clinical trials for Head and Neck Squamous Cell Carcinoma

BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer

Start date: June 1, 2018
Phase: Phase 2
Study type: Interventional

This phase IIa trial studies how well the experimental drug, BGJ398 (infigratinib), works in treating patients with fibroblast growth factor receptor (FGFR) 1-3 translocated, mutated, or amplified head and neck cancer that has returned after a period of improvement. BGJ398 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.